Deaya, Pfizer collaborate on clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Ideaya Biosciences Inc. and Pfizer Inc. have formed a clinical trial collaboration and supply agreement.

The collaboration includes an Ideaya-sponsored clinical combination study of IDE196, a protein kinase C inhibitor—and binimetinib, a MEK inhibitor that Pfizer has exclusive rights to in the U.S. and Canada, in GNAQ or GNA11 hotspot mutated solid tumors, including metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer.

Ideaya and Pfizer will form a joint development committee, and there will be joint decision making and data sharing of the clinical trial results between the parties. Ideaya will sponsor the study, and Pfizer will supply binimetinib for the study. The clinical combination trial is targeted to initiate in mid-2020.

The clinical combination study will evaluate whether inhibition of the MAP-kinase pathway at two nodes, through upstream PKC and downstream MEK, will enhance the response rate and depth and durability of clinical benefit in patients whose solid tumors harbor GNAQ or GNA11 hotspot mutations. The clinical trial will also study pharmacokinetics of each agent and tolerability of the combination.

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 
The Government Accountability Office, an independent, non-partisan congressional watchdog agency, found that NIH violated the Impoundment Control Act of 1974 when it cancelled nearly 2,000 research grants in an effort to comply with several of President Donald Trump’s executive orders, including “Ending Radical And Wasteful Government DEI Programs And Preferencing” (The Cancer Letter, Jan 24, 2025).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login